Prostate cancer with neuroendocrine differentiation is relatively rare, it is recommended that patients go to the hospital for timely examination and early treatment after diagnosis. Prostate cancer is a tumor that occurs in the ductal epithelium or follicular epithelium of the prostate gland. Prostate cancer with neuroendocrine differentiation generally indicates that the tumor has a higher degree of malignancy and progresses faster, which is a rare phenomenon in clinic. Patients can go to regular hospitals for surgical treatment in time. If the tumor cannot be completely removed by surgery, endocrine therapy can be used to control the tumor development by blocking the production and action of androgens. At present, it is known that neuroendocrine differentiation (NED) and neuroendocrine prostate cancer (NEPC) are important causes of prostate cancer resistance to debulking, which mostly occurs after long-term debulking treatment of CRPC. Prostate cancer patients with neuroendocrine (NE) features have poor response to chemotherapy and poor prognosis, with most surviving less than 1 year. If prostate cancer is suspected or diagnosed, it is recommended to go to a regular hospital for a comprehensive evaluation of the disease and follow the doctor’s instructions to avoid delaying the disease.